Randomised phase 2 trial of nivolumab and radiotherapy versus nivolumab alone in advanced non-small cell lung cancer progressing after first line chemotherapy
The aim of this study is to determine the activity and safety of treating an asymptomatic, extrapulmonary metastasis with a single fraction of SABR, during immunotherapy with nivolumab in advanced NSCLC progressing after 1 or 2 lines of chemotherapy.
Primary Sponsor
The University of Sydney
Collaborating Groups
Australasian Lung Cancer Trials Group (ALTG) and Trans Tasman Radiation Oncology Group (TROG)
Closing Date of Accrual
30 June 2019
Trial Chairperson
A/Prof Paul Mitchell, Austin Health, VIC
TROG Chair: Dr Shankar Siva, Peter MacCallum Cancer Centre, VIC
Trial Contact
nivorad@ctc.usyd.edu.au
Related Post
28 March, 2025
TROG Awards Recognise Research Excellence
Latest news: 28 March 2025. TROG Members who have
27 March, 2025
TROG 2025 ASM advances inclusivity and innovation
Latest news: 27 March 2025 With a theme of
